Cited by 232Multiple Sclerosis Research StudiesBarrier Structure and Function StudiesAdvanced MRI Techniques and Applications

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abnormal blood–brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI

Open access

Abstract

OBJECTIVES: To investigate whether blood-brain barrier (BBB) permeability is disrupted in normal appearing white matter in MS patients, when compared to healthy controls and whether it is correlated with MS clinical characteristics. METHODS: Dynamic contrast-enhanced MRI was used to measure BBB permeability in 27 patients with MS and compared to 24 matched healthy controls. RESULTS: Permeability measured as K(trans) was significantly higher in periventricular normal appearing white matter (NAWM) and thalamic gray matter in MS patients when compared to healthy controls, with periventricular NAWM showing the most pronounced difference. Recent relapse coincided with significantly higher permeability in periventricular NAWM, thalamic gray matter, and MS lesions. Immunomodulatory treatment and recent relapse were significant predictors of permeability in MS lesions and periventricular NAWM. Our results suggest that after an MS relapse permeability gradually decreases, possibly an effect of immunomodulatory treatment. CONCLUSIONS: Our results emphasize the importance of BBB pathology in MS, which we find to be most prominent in the periventricular NAWM, an area prone to development of MS lesions. Both the facts that recent relapse appears to cause widespread BBB disruption and that immunomodulatory treatment seems to attenuate this effect indicate that BBB permeability is intricately linked to the presence of MS relapse activity. This may reveal further insights into the pathophysiology of MS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nicl.2013.12.001

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 A) On a T2-weighted anatomical MRI sequence, with same geometry as the four acquired DCE perfusion slices, we placed regions of interest in periventricular normal appearing white matter (green), normal appearing gray matter (blue), thalamic gray matter (white), non-enhancing MS lesions (red) and contrast-enhancing MS lesions (white). B) Map of voxel-wise calculation of Ktrans values for one MS patient. Marked with a red arrow is a visibly enhancing MS lesion. Note also that the scalp is showing relatively high values of permeability, due to the presence of extracranial vessels not expressing a blood–brain barrier.
Fig. 1 A) On a T2-weighted anatomical MRI sequence, with same geometry as the four acquired DCE perfusion slices, we placed regions of interest in periventricular normal appearing white matter (green), normal appearing gray matter (blue), thalamic gray matter (white), non-enhancing MS lesions (red) and contrast-enhancing MS lesions (white). B) Map of voxel-wise calculation of Ktrans values for one MS patient. Marked with a red arrow is a visibly enhancing MS lesion. Note also that the scalp is showing relatively high values of permeability, due to the presence of extracranial vessels not expressing a blood–brain barrier.CC BY-NC-SA · PubMed Central
Fig. 2 Tissue enhancement curves, Patlak plots and derived parameters for one MS patient (left column) and one healthy control (right column). “Time” on the x-axis of the Patlak plot, corresponds to ∫0tCa(τ)dτ/Ca(t). Abbreviations: NAWM = normal appearing white matter. NEL = non-enhancing lesion. Vb = blood volume.
Fig. 2 Tissue enhancement curves, Patlak plots and derived parameters for one MS patient (left column) and one healthy control (right column). “Time” on the x-axis of the Patlak plot, corresponds to ∫0tCa(τ)dτ/Ca(t). Abbreviations: NAWM = normal appearing white matter. NEL = non-enhancing lesion. Vb = blood volume.CC BY-NC-SA · PubMed Central
Fig. 3 Permeability of the blood–brain barrier showing significantly higher values both in MS periventricular NAWM compared to cerebral white matter of healthy controls (p = 0.9 × 10− 5; one-tailed T test), and in thalamic gray matter (p = 0.003; one-tailed T test). Black line = median. Boxes = 25% and 75% percentiles. Whiskers = sample range, outliers marked by circles. NB! All outliers were included in statistical analysis.
Fig. 3 Permeability of the blood–brain barrier showing significantly higher values both in MS periventricular NAWM compared to cerebral white matter of healthy controls (p = 0.9 × 10− 5; one-tailed T test), and in thalamic gray matter (p = 0.003; one-tailed T test). Black line = median. Boxes = 25% and 75% percentiles. Whiskers = sample range, outliers marked by circles. NB! All outliers were included in statistical analysis.CC BY-NC-SA · PubMed Central
Fig. 4 In MS patients with clinical relapse within the last three months (n = 10), we found significantly higher permeability in periventricular NAWM (p = 0.004), thalamic gray matter (p = 0.004), and non-enhancing lesions (NELs) (p = 0.003; two-tailed T tests) compared to those with no relapse within three months. Immunomodulatory treatment coincided with significantly lower permeability in NEL (p = 0.01; two-tailed T test). Linear regression analysis showed that treatment (Beta = − 0.021 mL/100 g/min, p = 0.039) and relapse within the last three months (Beta = 0.034 mL/100 g/min, p = 0.001) were significant predictors of permeability in MS NEL. The overall model fit was R2 = 0.37 and p = 0.001 with no significant interaction between the two parameters. Values for healthy controls are added for comparison. Black line = median. Boxes = 25% and 75% percentiles. Whiskers = sample range, outliers marked by a circle. Treatment = immunomodulatory treatment with IFN-beta or glatiramer acetate. Relapse = one or more relapses within the last three months.
Fig. 4 In MS patients with clinical relapse within the last three months (n = 10), we found significantly higher permeability in periventricular NAWM (p = 0.004), thalamic gray matter (p = 0.004), and non-enhancing lesions (NELs) (p = 0.003; two-tailed T tests) compared to those with no relapse within three months. Immunomodulatory treatment coincided with significantly lower permeability in NEL (p = 0.01; two-tailed T test). Linear regression analysis showed that treatment (Beta = − 0.021 mL/100 g/min, p = 0.039) and relapse within the last three months (Beta = 0.034 mL/100 g/min, p = 0.001) were significant predictors of permeability in MS NEL. The overall model fit was R2 = 0.37 and p = 0.001 with no significant interaction between the two parameters. Values for healthy controls are added for comparison. Black line = median. Boxes = 25% and 75% percentiles. Whiskers = sample range, outliers marked by a circle. Treatment = immunomodulatory treatment with IFN-beta or glatiramer acetate. Relapse = one or more relapses within the last three months.CC BY-NC-SA · PubMed Central
Fig. 5 In MS patients receiving immunomodulatory treatment, we found the number of days since onset of last relapse to be a significant predictor of permeability in MS non-enhancing lesions (A), and periventricular normal appearing white matter (B). In the untreated group we found no such relation. Data points = mean value for each subject. Continuous line = logarithmic fit line; y = a − b∗log(x). R sq = R2. IFN-beta = interferon beta. GA = glatiramer acetate.
Fig. 5 In MS patients receiving immunomodulatory treatment, we found the number of days since onset of last relapse to be a significant predictor of permeability in MS non-enhancing lesions (A), and periventricular normal appearing white matter (B). In the untreated group we found no such relation. Data points = mean value for each subject. Continuous line = logarithmic fit line; y = a − b∗log(x). R sq = R2. IFN-beta = interferon beta. GA = glatiramer acetate.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 232

Metadata

Authors
Cramer, S. P., Simonsen, H., Frederiksen, J. L., Rostrup, E., & Larsson, H. B. W.
Affiliations
University of Copenhagen (DK)
Corresponding author
Cramer, S.P.
Venue
NeuroImage: Clinical
Publisher
Elsevier BV
Published
2014
Volume
4
Pages
182-189
ISSN
2213-1582 (ISSN-L)
OpenAlex
W2039561850
Cited by
232
References
37
Citations by year
2026: 16 · 2025: 20 · 2024: 16 · 2023: 20 · 2022: 24 · 2021: 16 · 2020: 14 · 2019: 20 · 2018: 26 · 2017: 13 · 2016: 16 · 2015: 21 · 2014: 9
FWCI
11.49
Type
journal article
Language
en
Open access
Locations
  • NeuroImage Clinical (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • BIBSYS Brage (BIBSYS (Norway)) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by-nc-sa)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • Biogen
  • Scleroseforeningen (14588)
  • Multiple Sclerosis Society (14588)
  • Region Hovedstaden
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
Keywords
multiple sclerosis, blood-brain barrier permeability, normal-appearing white matter, periventricular white matter, dynamic contrast-enhanced MRI, MS relapse, immunomodulatory therapy, MS lesions, blood-brain barrier disruption
MeSH terms
Adult, Blood-Brain Barrier, Capillary Permeability, Contrast Media, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Severity of Illness Index, Imaging, Three-Dimensional, Perfusion Imaging, White Matter

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review